Evidence supporting the use of: Oxymatrine
For the health condition: Cirrhosis of the Liver

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Oxymatrine and Cirrhosis of the Liver: Evidence Summary

Oxymatrine, an alkaloid extracted from the traditional Chinese medicinal plant Sophora flavescens, has been investigated for its effects on liver diseases, including cirrhosis. There is a growing body of preclinical evidence suggesting oxymatrine may exert anti-fibrotic, anti-inflammatory, and hepatoprotective effects. Animal studies have shown that oxymatrine can reduce hepatic fibrosis, decrease expression of pro-fibrotic cytokines (such as TGF-β1), and inhibit hepatic stellate cell activation, which are key processes in the development of cirrhosis.

Several small-scale clinical trials conducted in China have reported that oxymatrine, either alone or in combination with other treatments, may improve liver function, reduce serum fibrosis markers, and slow the progression of cirrhosis in patients with chronic hepatitis B or C. However, these studies are generally limited by small sample sizes, lack of rigorous controls, short follow-up periods, and methodological weaknesses. There is currently insufficient high-quality, large-scale randomized controlled trial data to firmly establish its efficacy or safety for cirrhosis of the liver.

In summary, while oxymatrine is supported by traditional use in Chinese medicine and preliminary scientific research, the clinical evidence is limited and of low-to-moderate quality. Thus, its use for cirrhosis of the liver is not yet broadly validated by robust scientific evidence.

More about Oxymatrine
More about Cirrhosis of the Liver

Products containing Oxymatrine

We currently have no products on Vitabase that contain this ingredient.